Antipsychotic News and Research RSS Feed - Antipsychotic News and Research

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
More genetic suspects for schizophrenia brought to light

More genetic suspects for schizophrenia brought to light

A meta-analysis from the Schizophrenia Working Group of the Psychiatric Genomics Consortium has revealed a large number of previously unreported genetic loci that may have a role in schizophrenia. [More]
Study suggests possible link between immune system and schizophrenia

Study suggests possible link between immune system and schizophrenia

Nancy Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant Professor of Clinical Nursing at LSU Health Sciences Center New Orleans School of Nursing, contributed samples used in a study reporting new locations of genetic material associated with schizophrenia and also suggesting a possible link between the immune system and schizophrenia. [More]
Study confirms link between antipsychotic medication and slight decrease in brain volume

Study confirms link between antipsychotic medication and slight decrease in brain volume

A study published today has confirmed a link between antipsychotic medication and a slight, but measureable, decrease in brain volume in patients with schizophrenia. [More]
Very-late-onset schizophrenia linked to particularly high mortality risk

Very-late-onset schizophrenia linked to particularly high mortality risk

Patients with very-late-onset schizophrenia-like psychosis have an increased risk of death compared with both the general population and patients with schizophrenia diagnosed earlier in life, Finnish study findings indicate. [More]
Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%. [More]
Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

This report estimated the effect of the Affordable Care Act (ACA) on 14 large and diverse cities: Los Angeles, Chicago, Houston, Philadelphia, Phoenix, Indianapolis, Columbus, Charlotte, Detroit, Memphis, Seattle, Denver, Atlanta, and Miami. [More]
Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes plc today announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Fla. [More]
Cognitive decline not apparent in bipolar patients

Cognitive decline not apparent in bipolar patients

Cognitive dysfunction is persistent but generally stable over time in patients with bipolar disorder, Spanish researchers report. [More]
Brain circuit problem may contribute to auditory hallucinations of schizophrenia

Brain circuit problem may contribute to auditory hallucinations of schizophrenia

St. Jude Children's Research Hospital scientists have identified problems in a connection between brain structures that may predispose individuals to hearing the "voices" that are a common symptom of schizophrenia. The work appears in the June 6 issue of the journal Science. [More]

Study offers clues to best long-acting injectable antipsychotic use

Findings from the PROACTIVE study suggest why the benefits of long-acting injectable second-generation antipsychotics may be difficult to detect in a clinical trial. [More]
EC approves extension of INVEGA antipsychotic drug to include adolescents aged 15 years and older

EC approves extension of INVEGA antipsychotic drug to include adolescents aged 15 years and older

Janssen-Cilag International NV announced today that the European Commission has approved an extension of the oral atypical antipsychotic INVEGA® (paliperidone ER) schizophrenia indication, to include adolescents aged 15 years and older. [More]
Study: Use of antipsychotic medication during pregnancy can affect babies

Study: Use of antipsychotic medication during pregnancy can affect babies

A seven-year study of women who take antipsychotic medication while pregnant, proves it can affect babies. [More]
Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia. [More]
Bipolar remission influenced by anxiety and OCD

Bipolar remission influenced by anxiety and OCD

Anxiety disorders and obsessive compulsive disorder may reduce the likelihood of achieving remission for patients with bipolar disorder, study findings indicate. [More]
Drug use linked to persistent violence in psychosis patients

Drug use linked to persistent violence in psychosis patients

Patients with first-episode psychosis are more likely to report being involved in violence over subsequent years if they persist with illicit drug use, a 10-year study shows. [More]
Existing pharmaceutical drugs may offer effective therapies against MERS

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS). [More]
Antipsychotic use linked to reduced patient violence

Antipsychotic use linked to reduced patient violence

Prescribing antipsychotics may reduce psychiatric patients’ propensity to commit violent crime, a study in The Lancet suggests. [More]
Salk scientists explore earliest detectable changes in the brain that lead to schizophrenia

Salk scientists explore earliest detectable changes in the brain that lead to schizophrenia

Using new stem cell technology, scientists at the Salk Institute have shown that neurons generated from the skin cells of people with schizophrenia behave strangely in early developmental stages, providing a hint as to ways to detect and potentially treat the disease early. [More]

Antipsychotic medication can reduce violent crime among people with psychiatric illness

New data indicate that people with psychiatric illness are almost half as likely to commit a violent crime when taking antipsychotic medication (such as clozapine or risperidone) compared with when they are not using such medication. The reduction in violent crime was smaller with use of mood stabilising drugs (such as lithium or carbamazepine) and only apparent among male patients with bipolar disorder. [More]

Antipsychotic medication reduces violent crime rates

People who use antipsychotic medication (such as clozapine or risperidone) to treat psychiatric illness are nearly half as likely to commit a violent crime compared to when they are not using such medication, according to new results published in The Lancet. [More]